Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Prokocimer P, De Anda C, Fang E, Mehra P, Das A.

JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.

PMID:
23403680
2.

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review.

PMID:
25673021
3.

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.

O'Riordan W, Green S, Mehra P, De Anda C, Fang E, Prokocimer P.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S43-50. doi: 10.1093/cid/cit617. Review.

PMID:
24343832
4.

Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.

Burdette SD, Trotman R.

Clin Infect Dis. 2015 Oct 15;61(8):1315-21. doi: 10.1093/cid/civ501. Epub 2015 Jun 23. Review.

PMID:
26105167
5.

Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

McBride D, Krekel T, Hsueh K, Durkin MJ.

Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):331-337. doi: 10.1080/17425255.2017.1290080. Epub 2017 Feb 16. Review.

PMID:
28140693
6.

Tedizolid for treatment of acute bacterial skin and skin structure infections.

Hui Y, Xiaoju L.

Expert Rev Anti Infect Ther. 2015;13(9):1051-60. doi: 10.1586/14787210.2015.1073107. Epub 2015 Jul 27. Review.

PMID:
26211946
7.

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.

Urbina O, Ferrández O, Espona M, Salas E, Ferrández I, Grau S.

Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Print 2013. Review.

8.

Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.

Rybak JM, Marx K, Martin CA.

Pharmacotherapy. 2014 Nov;34(11):1198-208. doi: 10.1002/phar.1491. Epub 2014 Sep 30. Review.

PMID:
25266820
9.

Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.

Chahine EB, Sucher AJ, Knutsen SD.

Consult Pharm. 2015 Jul;30(7):386-94. doi: 10.4140/TCP.n.2015.386. Review.

PMID:
26173190
10.

Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.

Ferrández O, Urbina O, Grau S.

Drug Des Devel Ther. 2016 Dec 22;11:65-82. doi: 10.2147/DDDT.S84667. eCollection 2017. Review.

11.

Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections.

Hall RG 2nd, Michaels HN.

Infect Drug Resist. 2015 Apr 22;8:75-82. doi: 10.2147/IDR.S56691. eCollection 2015. Review.

12.

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.

Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S51-7. doi: 10.1093/cid/cit618. Review.

PMID:
24343833
13.

Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.

Russo A, Concia E, Cristini F, De Rosa FG, Esposito S, Menichetti F, Petrosillo N, Tumbarello M, Venditti M, Viale P, Viscoli C, Bassetti M.

Clin Microbiol Infect. 2016 Apr;22 Suppl 2:S27-36. doi: 10.1016/S1198-743X(16)30095-7. Review.

14.

Tedizolid: a new oxazolidinone antimicrobial.

Kisgen JJ, Mansour H, Unger NR, Childs LM.

Am J Health Syst Pharm. 2014 Apr 15;71(8):621-33. doi: 10.2146/ajhp130482. Review.

PMID:
24688035
15.

New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.

Durkin MJ, Corey GR.

Ther Clin Risk Manag. 2015 May 22;11:857-62. doi: 10.2147/TCRM.S64553. eCollection 2015. Review.

16.

Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Lodise TP, Low DE.

Drugs. 2012 Jul 30;72(11):1473-93. doi: 10.2165/11635660-000000000-00000. Review.

PMID:
22779432
17.

Tedizolid for the management of human infections: in vitro characteristics.

Locke JB, Zurenko GE, Shaw KJ, Bartizal K.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S35-42. doi: 10.1093/cid/cit616. Review.

PMID:
24343830
18.

Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.

Douros A, Grabowski K, Stahlmann R.

Expert Opin Drug Metab Toxicol. 2015;11(12):1849-59. doi: 10.1517/17425255.2015.1098617. Epub 2015 Oct 12. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2015;11(12):v.

PMID:
26457865
19.

Linezolid versus vancomycin for skin and soft tissue infections.

Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ.

Cochrane Database Syst Rev. 2016 Jan 7;(1):CD008056. doi: 10.1002/14651858.CD008056.pub3. Review.

PMID:
26758498
20.

Linezolid versus vancomycin for skin and soft tissue infections.

Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ.

Cochrane Database Syst Rev. 2013 Jul 12;(7):CD008056. doi: 10.1002/14651858.CD008056.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(1):CD008056.

PMID:
23846850

Supplemental Content

Support Center